FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin Unresponsive Non-Muscle Invasive Bladder Cancer
Evidence for efficacy is based on the results from the Study CS-003
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Higher Event-Free Survival with Addition of Crizotinib to a Standard Chemotherapy Backbone for Children with ALK-positive Anaplastic Large-Cell Lymphoma
An unexpected increase in the number of thromboembolic events observed in crizotinib arm of the ANHL12P1 study
Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals After Up To 5 Years of Follow-Up in Patients with Metastatic Urothelium Cancer
Findings from the KEYNOTE-045 study in patients with platinum-resistant metastatic urothelial cancer and from the KEYNOTE-052 as first-line treatment for cisplatin-ineligible patients
Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity in Patients with Localised dMMR Solid Tumours
The results of a phase II study of neoadjuvant pembrolizumab for patients with localised mismatch repair deficient/microsatellite instability-high solid tumours
Implementation of the Clinical Trials Regulation in the EU and EEA
The Clinical Trials Information System will become mandatory for all authorisation application for a clinical trial in the EU on 31 January 2023
FDA Grants Accelerated Approval to Mosunetuzumab-axgb for Relapsed or Refractory Follicular Lymphoma
Evidence for efficacy is based on the results from the GO29781 study
Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with Cetuximab, and Reversible Side Effects in Patients with Previously Treated KRAS G12C–Mutated mCRC
Findings from the ongoing KRYSTAL-1 phase I/II study in patients with metastatic colorectal cancer with a KRAS G12C mutation
Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously Treated KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Findings from the phase I and phase II portions of the CodeBreaK 100 study
FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens for Capecitabine Tablets
It is the first drug to receive a labelling update under Project Renewal
EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a Positive Opinion for Tremelimumab
New indications concern the combination treatment of metastatic non-small cell carcinoma and of advanced or unresectable hepatocellular carcinoma
EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan
New indication concerns the treatment of unresectable or metastatic HER2-low breast cancer
Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas
Different molecular subtypes of appendiceal adenocarcinomas have distinct clinical and biological behaviours that may be useful in guiding therapeutic decision